Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracil
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Adenocarcinoma
Conditions
Adenocarcinoma
Trial Timeline
Sep 1, 2007 → Nov 1, 2013
NCT ID
NCT00548548About Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracil
Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracil is a phase 3 stage product being developed by Chugai Pharmaceutical for Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00548548. Target conditions include Adenocarcinoma.
What happened to similar drugs?
1 of 20 similar drugs in Adenocarcinoma were approved
Approved (1) Terminated (1) Active (18)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00548548 | Phase 3 | Completed |
Competing Products
20 competing products in Adenocarcinoma